{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-009462","form_type":"8-K","ticker":"CELU","cik":"0001752828","company_name":"Celularity Inc","filed_at":"2025-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.587638+00:00","generated_at":"2026-05-22T01:56:20.838752+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Celularity reports 2024 revenue of $54.2M, up 138% YoY; operating loss narrows 80%","bullets":["Net revenues $54.2M, up 138.1% YoY; product sales in wound care up 168.7% to $35.3M.","Operating expenses fell 57% to $92.6M; loss from operations improved 80.1% to $38.4M.","Received FDA Tissue Reference Group recommendation letters for new placental-derived biomaterial products.","Cash and cash equivalents $738K at Dec 31, 2024, up from $227K prior year.","Total assets $132.7M; stockholders' equity $8.8M at year-end 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-009462","json":"https://secwatch.observer/filing/0001641172-25-009462.json","markdown":"https://secwatch.observer/filing/0001641172-25-009462.md","text":"https://secwatch.observer/filing/0001641172-25-009462.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1752828/000164117225009462/0001641172-25-009462-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1752828/000164117225009462/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T01:56:20.838752+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}